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Abstract 
Background: The prognostic score of the International Germ Cell Cancer Collaborative 
Group (IGCCCG) in metastatic germ-cell cancers (mGCC) relies on treatments delivered 
before 1990. It is unclear, if this score is still relevant to contemporary cohorts of patients 
who receive modern-type chemotherapy and supportive care. 
Patients and Methods: All patients who underwent cisplatin/etoposide based first-line 
chemotherapy for mGCC at the University Hospital Zurich (USZ) between 1991 and 2016 
were identified retrospectively. Clinical characteristics were extracted from medical charts 
and patients classified according to the IGCCCG score (J Clin Oncol 1997;15:594). 
Progression-free survival (PFS) and overall survival (OS) probabilities at 5 years served as 
outcome parameters. 
Results: The study cohort consisted of 204 patients at a median age of 32 years and a median 
follow-up of 4.2 years. According to the IGCCCG score, PFS in the contemporary USZ 
cohort was 71% overall; 83% for good risk, 69% for intermediate risk and 30% for poor risk 
patients, p<0.001. OS for the entire cohort was 88%. In respect to OS, we observed no 
difference between good risk and intermediate risk patients (94% vs. 91%, p=0.62), but a 
statistically significant difference between those two risk groups and poor risk patients, who 
had an OS of only 65%, p<0.001. 
Conclusions: Within the contemporary USZ cohort of mGCC patients no improvements in 
PFS probabilities were observed compared to the ones predicted by the IGCCCG score for 
any prognostic category, but marked improvements in OS probabilities for intermediate risk 
and poor risk patients, possibly due to better salvage treatments. 
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Introduction 
In 2017, an estimated number of 8,850 new cases of germ-cell cancers (GCC) will be 
diagnosed in the United States. [1] Although GCC show a high sensitivity to cisplatin-based 
chemotherapy, 10-15% of patients fail first-line treatment and 3-5% of all GCC patients will 
eventually die of their disease. [2] In 1997, the International Germ-Cell Cancer Cooperative 
Group (IGCCCG) published a prognostic classification for metastatic GCC (mGCC) to direct 
and optimize treatments. [3] The resulting IGCCCG score has become the reference for 
treatment decisions in mGCC ever since. However, as the IGCCCG score relies on treatments 
delivered between 1975 and 1990 and as diagnostic and therapeutic standards as well as 
supportive care have improved substantially since that time, this study aimed to assess the 
performance of the IGCCCG score in a contemporary patient cohort. 
 
Patients and methods 
All patients who underwent first-line chemotherapy at the University Hospital Zurich (USZ) 
between 1991 and 2016 for mGCC were identified. Inclusion criteria for the analysis were 
modern type combination chemotherapy consisting of at least three or more cycles of 
cisplatin and etoposide with or without bleomycin or ifosfamide. The year 1991 war chosen 
as a starting point for the analysis as the combination of cisplatin, etoposide and bleomycin 
(BEP) was routinely used at the USZ since the publication of Williams et al demonstrating 
superiority of BEP over the vinblastine contaning combination in 1987. [4] Bleomycin was 
either omitted or replaced by ifosfamide in the event of contraindications to this drug. Also 
high-dose chemotherapy using carboplatin and etoposide was introduced in 1990 as salvage 
treatment at the USZ after the initial publication of Nichols et al. [5] 
All patients with residual tumors after chemotherapy were routinely scheduled for post-
chemotherapy surgery. Patients with relapse or progression after first-line treatment were 
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scheduled for salvage treatment based individually on relapse presentation and risk factors at 
the time. 
We extracted clinical characteristics such as age at diagnosis, location of primary tumor, 
histology, location of metastases, levels of alpha-fetoprotein (AFP), human chorionic 
gonadotropin (HCG) and lactate dehydrogenase (LDH) from electronic medical charts and 
calculated the individual IGCCCG score for each patient. [3] The study was approved by the 
local ethics committee (STV KEK-ZH 25-2008). 
The endpoints of the study were the progression-free survival (PFS) and overall survival (OS) 
probabilities at 5 years. PFS started with the initiation of chemotherapy and ended with 
progression or death, whichever occurred first. OS started with the initiation of chemotherapy 
and ended with the death of a patient. Survival status was identified from medical charts or 
death certificates. Patients without an event were censored at the date of last follow-up. 
PFS and OS were calculated according to the Kaplan-Meier method and compared using the 
log-rank test. Survival probabilities are reported together with the corresponding standard 
error (SE) and 95% confidence intervals (95% CI). Statistical analyses were performed using 
the STATA software Version 10.0 (StataCorp LLC, College Station, Texas, USA). Continuous 
non-normally distributed variables are presented as median and interquartile ranges (IQR) 
and categorical variables are presented as percentages. Probabilities p <0.05 were considered 
statistically significant. All statistical tests were two-sided. 
 
Results 
Patients characteristics 
The final study cohort consisted of 204 patients at a median age of 32 years (IQR 26-39 
years) and median follow-up time of 4,2 years (IQR 1,9-7,8 years) (Table 1). Among 195 
patients with known histological subtype, 52/195 (27%) patients had pure seminoma and 
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143/195 (73%) had non-seminoma or mixed histologies. Details of other patient 
characteristics are shown as table 1. 
The contemporary USZ cohort was comparable to the historical IGCCCG cohort. Imbalances 
were found for the number of seminoma patients and patients with mediastinal primary 
tumors, which were more frequent in the contemporary cohort. Patients with brain metastases 
were more frequent in the historical cohort. 
Despite these imbalances, the historical IGCCCG and the contemporary USZ cohort showed 
similar distributions in respect to the IGCCCG risk groups, with 60% versus 62% low risk 
patients, 26% versus 19% intermediate risk patients and 14% versus 19% poor risk patients, 
respectively. Compared to the historical IGCCCG cohort less intermediate risk and slightly 
more good risk and poor risk patients were observed (Table 2). 
In the contemporary USZ cohort treatment consisted of three or four cycles of BEP in 
184/204 (90%) patients, cisplatin and etoposide (EP) in 6/204 (3%) patients, cisplatin, 
etoposide and ifosfamide in 8/204 (4%) patients and other cisplatin- and etoposide-based 
regimens in 6/204 (3%) patients. Overall 57/204 (28%) relapses occurred, 9/52 (17%) among 
patients with pure seminoma, and 48/143 (34%) among patients with non-seminoma or 
mixed histologies. Salvage treatment in relapsed patients consisted of surgery alone in 12/57 
(21%) patients with teratoma, conventional-dose cisplatin-based chemotherapy (CDCT) in 
13/57 (23%) patients, sequential high-dose chemotherapy (HDCT) with carboplatin and 
etoposide in 23/57 (40%) patients, and CDCT followed by HDCT in 7/57 (12%) patients. 
Two patients died before any salvage treatment could be given (table 3). Residual tumor 
resections after completion of salvage chemotherapy were performed in 17/43 (40%) patients. 
OS in relapsing as compared to non-relapsing patients is shown as supplemental figure S1. 
 
Survival 
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The published IGCCCG score correctly divided the contemporary USZ cohort into three 
distinct and significantly different groups for PFS with probabilities of 83% (SE: 3.6%; 75% 
CI: 85% to 89%), 69% (SE: 8%; 95% CI: 50% to 82%) and 30% (SE: 10%; 95% CI: 13% to 
50%) at 5 years (p<0.001) (Figure 1). These probabilities are very similar to the predicted 
ones according to the published IGCCCG score (Table 2). 
The OS probabilities in the contemporary USZ cohort were 95% (SE: 2.1%; 95% CI: 89% to 
98%), 91% (SE: 4.8%; 95% CI: 76% to 97%), and 65% (SE: 8.9%; 95% CI: 44% to 79%) for 
good risk, intermediate risk and poor risk patients, respectively. Compared to the OS 
probabilities predicted by the published IGCCCG score, this represents a marked 
improvement in OS among intermediate and poor risk patients, and only a slight 
improvement among good risk patients in the contemporary USZ cohort (Figure 2). In respect 
to OS, the IGCCCG score did no longer predict separate probabilities for the groups of good 
and intermediate risk patients (p=0.62). Only OS for poor risk patients was correctly 
predicted by the historical IGCCCG score with a significantly inferior OS probability 
compared to good and intermediate risk patients (p<0.001). 
 
Discussion 
Substantial improvements in diagnostic and therapeutic standards have occurred since the 
introduction of cisplatin into the treatment of mGCC. Our present retrospective analysis, 
however, demonstrated that the observed PFS probabilities for mGCC after first-line 
chemotherapy did not differ compared to the ones predicted by the IGCCCG score despite 
these improvements. Although, the IGCCCG score, which was developed based on 
treatments delivered between 1975 and 1990, still correctly divided our more contemporary 
USZ cohort treated between 1991 and 2016 into three risk groups based on their PFS, the 
PFS probabilities within these three risk groups have not improved. Possibly the efficacy of 
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cisplatin-based treatment had already been high in the IGCCCG cohort so that further 
improvements might have been too small to be detected, the rate of treatment-related deaths 
might have been too low and the contemporary patient cohort studied too small to detect any 
improvements in first-line treatment that may have occurred since 1990. Treatment 
intensification using dose-dense or upfront high-dose chemotherapy in poor risk patients, in 
whom most of the benefit of treatments intensification can be expected, had not been used 
during the study period at our center. [6] 
In contrast, the observed OS probabilities have markedly improved particularly among 
intermediate risk and poor risk patients in the contemporary USZ cohort as compared to the 
OS probabilities predicted by the IGCCCG score. The OS probabilities at 5 years increased 
from 91% as predicted to 95% observed among good risk patients, from 79% as predicted to 
91% observed among intermediate risk patients and from 48% as predicted to 65% observed 
among poor risk patients. With these improvements the observed OS probabilities among the 
IGCCCG risk groups were no longer different between the good and intermediate risk 
patients (p=0.62), but still significantly different between those two risk groups and poor risk 
patients (p<0.001). The comparison of the probabilities for PFS and OS as predicted by the 
published IGCCCG score and the ones observed in our contemporary USZ cohort produced 
three important findings. 
First, the IGCCCG score is no longer prognostic for OS among intermediate risk patients. In 
our contemporary USZ cohort the good risk and intermediate risk groups showed similar OS 
probabilities indicating that the IGCCCG score no longer separates these two risk groups 
sufficiently well. Modifications of the published IGCCCG score with better discrimination of 
intermediate risk and poor risk patients have been suggested in an attempt to avoid 
overtreatment as well as undertreatment of mGCC patients. [11] 
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Second, since early 1970, improvements in diagnosis and treatment of GCC have mainly 
consisted in better staging using computed tomography (CT) and magnetic resonance 
tomography (MRT) scans as well as improved supportive care. Apart from etoposide with 
superior activity compared to vinblastine, no new active agent has been introduced into the 
standard first-line treatment of mGCC. [4] Therefore the current recommendation for first-
line treatment remains three to four cycles BEP or EP depending on the IGCCCG risk group. 
[7-10] Very recently only, intensive dose-dense combination chemotherapy has demonstrated 
superior PFS, but not OS in a cohort of poor-risk patients with an unfavorable marker decline 
after the first-cycle of BEP. [6] While current improvements in supportive care have certainly 
improved tolerability of cisplatin-based combination treatment, our data demonstrates 
comparable PFS probabilities between the PFS as predicted by the IGCCCG score and the 
observed PFS in our contemporary USZ cohort. This confirms the limited improvements in 
efficacy of conventional-dose first-line treatments of mGCC since early 1970. 
Third, there are several explanations for an improved OS in mGCC patients in our more 
contemporary cohort. Better diagnostic tools and structured follow-up schedules might have 
resulted in the earlier diagnosis of relapses occurring in patients with less advanced disease. 
Improvements in supportive care with better management of infectious complications, less 
treatment delays due to the availability of hematopoietic growth factors as well as more 
experience in the management of organ toxicities might have had a greater impact after the 
more toxic salvage as compared to the less toxic first-line treatment. However, the biggest 
contribution to the improvements in OS comes from better salvage strategies that have 
changed substantially since 1990. Conventional-dose first salvage chemotherapy has 
integrated new drugs with single agent activity in cisplatin-refractory patients such as 
ifosfamide and paclitaxel. [12,13] High-dose chemotherapy is being used more regularly as 
first or subsequent salvage treatment. [14,15] Salvage surgery is being applied more 
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aggressively. [16] And finally effective third-line treatment options have become available 
integrating gemcitabine and oxaliplatin with reported long-term survivors even in 
prognostically unfavorable groups of patients. [17] With the lack of prospective randomized 
trials, however, it will be impossible to dissect the individual contribution of each of these 
interventions, which are all reflected in our contemporary patient cohort studied. 
The present analysis is limited by its retrospective design, single center approach and small 
sample size. Moreover, we were only able to compare the survival probabilities predicted by 
the IGCCC score to the ones actually observed at our center. As we did not have access to the 
original IGCCCG data, we cannot make, and did not intend to perform direct comparisons 
between the initial IGCCCG cohort and our contemporary patient cohort. Patients referred to 
a tertiary cancer center will always be selected and will not be representative for the 
population of all mGCC patients. An analysis of a larger, less selected and multicenter cohort 
and a comparison to the original IGCCCG data might result in different findings. However, 
almost identical results have been presented from Germany at the meeting of the European 
Society of Medical Oncology among patients treated within a community service. [18] 
Finally, unknown confounders other than the ones mentioned above may have impacted on 
the better OS probabilities observed in the contemporary USZ cohort. However, despite these 
shortcomings the present analysis is hypothesis generating and provides the rationale for an 
ongoing international multi-center effort to study the results of modern type chemotherapy in 
a much larger and less selected patient cohort of mGCC. 
 
Key Messages 
We assessed the performance the prognostic score of the International Germ-Cell Cancer 
Collaborative Group (IGCCCG) in a contemporary patient cohort. The observed PFS 
probabilities were not different to the ones predicted. In contrast, the observed OS 
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probabilities had markedly improved particularly in intermediate and poor risk patients most 
likely as a result of better salvage treatments. 
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Figure 1: Progression-free survival probabilities in the contemporary 
  cohort of the University Hospital Zurich (n=204) 
 
 
 
 
 
Figure 2: Overall survival probabilities in the contemporary cohort of 
  the University Hospital Zurich (n=204) 
 
 
Figure S1: Overall survival probabilities in patients with (n=147) and 
  without (n=57) progression after first-line treatment 
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Table 1: Comparison of patient characteristics of the published IGCCCG 
  cohort and the contemporary cohort 
 
USZ = University Hospital Zurich; AFP = Alpha-fetoprotein; HCG = Human chorionic 
gonadotropin, IGCCCG = International; Germ Cell Cancer Collaborative Group, 
LDH = Lactat dehydrogenase; n.a. = not available 
  
IGCCCG cohort n=5889 
(1975-1990) 
USZ cohort n=204 
(1991-2016) 
Age 
<20 
20-29 
30-39 
40-49 
≥50 
5862/5889 
562 (10%) 
2808 (48%) 
1674 (28%) 
573 (10%) 
272 (4%) 
204/204 
10 (5%) 
72 ( 35%) 
73 (36%) 
38 (19%) 
11 (5%) 
Primary tumor 
Gonadal 
Extragonadal 
5862/5889 
5423/5862 (93%) 
439/5862 (7%) 
204/204 
171/204 (84%) 
33/204 (16%) 
Histology 
Seminoma 
Non-Seminoma or mixed 
5862/5889 
660/5862 (11%) 
5202/5862 (89%) 
195/204 
52/195 (27%) 
143/195 (73%) 
Location of metastases 
Abdominal 
Mediastinal 
Neck mass 
Lung 
Liver 
Bone 
Brain 
 
3705/5060 (73%) 
610/5091 (12%) 
570/5022 (11%) 
3375/5712 (40%) 
360/5784 (6%) 
85/5574 (2%) 
870/5572 (16%) 
 
176/204 (86%) 
60/202 (29%) 
26/201 (13%) 
80/203 (39%) 
14/204 (7%) 
9/203 (4%) 
6/203 (3%) 
AFP 
   <1000 
   1000-10.000 
   >10.000 
5748/5889 
4275/5748 (86%) 
602/5748 (10%) 
211/5748 (4%) 
128/204 
112/128 (87%) 
13/128 (10%) 
3/128 (2%) 
HCG 
   <1000 
   1000-10.000 
   >10.000 
5769/5889 
5072/5769 (88%) 
384/5769 (7%) 
313/5769 (5%) 
133/204 
98/133 (73%) 
17/133 (13%) 
18/133 (14%) 
LDH 
   <1.5x upper limit 
   1.5-10x upper limit 
   >10x upper limit 
3720/5889 
2413/3720(65%) 
1245/3720 (33%) 
62/3720 (2%) 
115/204 
81/115 (70%) 
33/115 (29%) 
1/115 (1%) 
IGCCCG risk groups 
   Good 
   Intermediate 
   Poor 
 
n.a. (60%) 
n.a. (26%) 
n.a. (14%) 
 
127/204 (62%) 
39/204 (19%) 
38/204 (19%) 
Table 2: Comparison of progression free survival (PFS) and overall survival 
   (OS) probabilities as predicted by the IGCCCG score and the ones 
   observed in the contemporary USZ cohort 
 
 Good risk Intermediate risk Poor risk 
 
Predicted 
by the 
IGCCCG 
score 
Observed 
in the USZ 
cohort 
(n=127) 
Predicted 
by the 
IGCCCG 
score 
Observed 
in the USZ 
cohort 
(n=39) 
Predicted 
by the 
IGCCCG 
score 
Observed 
in the USZ 
cohort 
(n=38) 
Treatments (1975-1990) (1991-2016) (1975-1990) (1991-2016) (1975-1990) (1991-2016) 
Percent of 
entire cohort 60% 62% 26% 19% 14% 19% 
PFS at 5 years 88% 83% (75%-89%)* 75% 
69% 
(50%-82%)* 41% 
30% 
(13%-50%)* 
OS at 5 years 91% 95% (89%-98%)* 79% 
91% 
(76%-97%)* 48% 
65% 
(44%-79%)* 
IGCCCG= International Germ Cell Cancer Collaborative Group (J Clin Oncol 1997;15:594); 
USZ = University Hospital Zurich; * 95% confidence interval 
Table 3: Salvage strategies after failure of first-line treatment * 
 
 
Salvage strategy Pat. Surgery Outcome 
    
Only surgery 12 - 11 alive and in remission 
  1 lost-to follow 
    
CDCT 13 no   3 alive and in remission 
  4 died 
  yes   2 alive and in remission 
  1 alive with disease 
  3 died 
    
HDCT 23 no 11 alive and in remission 
  1 lost-to-follow 
  4 died 
  yes   4 alive and in remission 
  1 lost-to-follow 
  2 died 
    
CDCT and HDCT 7 no   3 died 
  yes   1 alive and in remission 
  3 died 
    
 2    2 died before treatment 
 
Legend: Pat. = number of patients; CDCT = conventional-dose chemotherapy; 
  HDCT = high-dose chemotherapy; remission = complete remission or 
  partial remission with negative serum tumor markers. 
  * Overall survival probabilities in relapsing as compared to non-relapsing 
  patients are shown as supplemental figure S1. 
